NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company that is dedicated to developing innovative therapies for neurodegenerative, infectious, and cardiometabolic diseases. The company’s current therapeutics programs include ANA001, an oral niclosamide formulation that is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19.

NeuroBo Pharmaceuticals, Inc. was founded in 2017 by a team of experienced life science professionals with a shared vision of creating innovative therapies for patients with serious diseases. The company is headquartered in Boston, Massachusetts and has a number of research and development sites across the United States. Additionally, the company has strategic collaborations with several leading pharmaceutical companies to leverage their expertise and resources to further develop its therapies.

NeuroBo Pharmaceuticals, Inc. is committed to developing treatments that have the potential to improve the lives of patients with serious diseases. The company is focused on advancing its therapeutic programs through clinical trials and strategic collaborations to bring its therapies to market. The company is also actively exploring new opportunities to expand its therapeutic pipeline and develop additional treatments for patients.